Interferons, immunity and cancer immunoediting (original) (raw)

• Burnet, F. M. Cancer: a biological approach. III. Viruses associated with neoplastic conditions. IV. Practical applications. Br. Med. J. 1, 841–847 (1957).
  CAS PubMed PubMed Central Google Scholar
• Thomas, L. in Cellular and Humoral Aspects of the Hypersensitive States (ed. Lawrence, H. S.) 529–532 (Hoeber–Harper, New York, 1959).
  Google Scholar
• Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J. & Schreiber, R. D. Cancer immunoediting: from immunosurveillance to tumor escape. Nature Immunol. 3, 991–998 (2002). The first review of the concept of cancer immunoediting, with a focus on the historical evolution of the concept.
  CAS Google Scholar
• Dunn, G. P., Old, L. J. & Schreiber, R. D. The three Es of cancer immunoediting. Annu. Rev. Immunol. 22, 329–360 (2004). A comprehensive review of the concept of cancer immunoediting, including extensive discussion of evidence that cancer immunoediting also occurs in humans.
  CAS PubMed Google Scholar
• Dunn, G. P., Old, L. J. & Schreiber, R. D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21, 137–148 (2004).
  CAS PubMed Google Scholar
• Shankaran, V. et al. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410, 1107–1111 (2001). Reveals the dual function — both host protective and tumour sculpting — of cancer immunoediting.
  CAS PubMed Google Scholar
• Smyth, M. J., Dunn, G. P. & Schreiber, R. D. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv. Immunol. 90, 1–50 (2006).
  CAS PubMed Google Scholar
• Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70 (2000). A seminal review that discusses the essential hallmarks of cancer.
  CAS PubMed Google Scholar
• Dunn, G. P. et al. A critical function for type I interferons in cancer immunoediting. Nature Immunol. 6, 722–729 (2005). Describes the host-protective and tumour-sculpting activities of type I IFNs in cancer immunoediting.
  CAS Google Scholar
• Takeda, K. et al. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J. Exp. Med. 195, 161–169 (2002). Reveals an overlapping role for TRAIL and IFNγ in cancer immunoediting.
  CAS PubMed PubMed Central Google Scholar
• Crowe, N. Y., Smyth, M. J. & Godfrey, D. I. A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J. Exp. Med. 196, 119–127 (2002). Demonstrates the importance of NKT cells that express a semi-invariant T-cell receptor containing Jα281 and their IFNγ-producing capacity in cancer immunoediting.
  CAS PubMed PubMed Central Google Scholar
• Decker, T., Muller, M. & Stockinger, S. The Yin and Yang of type I interferon activity in bacterial infection. Nature Rev. Immunol. 5, 675–687 (2005).
  CAS Google Scholar
• Berenson, L. S., Ota, N. & Murphy, K. M. Issues in T-helper 1 development — resolved and unresolved. Immunol. Rev. 202, 157–174 (2004).
  CAS PubMed Google Scholar
• Bach, E. A., Aguet, M. & Schreiber, R. D. The IFNγ receptor: a paradigm for cytokine receptor signaling. Annu. Rev. Immunol. 15, 563–591 (1997).
  CAS PubMed Google Scholar
• Boehm, U., Klamp, T., Groot, M. & Howard, J. C. Cellular responses to interferon-γ. Annu. Rev. Immunol. 15, 749–795 (1997).
  CAS PubMed Google Scholar
• Stark, G. R., Kerr, I. M., Williams, B. R., Silverman, R. H. & Schreiber, R. D. How cells respond to interferons. Annu. Rev. Biochem. 67, 227–264 (1998).
  Article CAS PubMed Google Scholar
• Dighe, A. S., Richards, E., Old, L. J. & Schreiber, R. D. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFNγ receptors. Immunity 1, 447–456 (1994).
  CAS PubMed Google Scholar
• Kaplan, D. H. et al. Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice. Proc. Natl Acad. Sci. USA 95, 7556–7561 (1998). Original description of the importance of IFNγ in cancer immunosurveillance.
  CAS PubMed PubMed Central Google Scholar
• Street, S. E., Cretney, E. & Smyth, M. J. Perforin and interferon-γ activities independently control tumor initiation, growth, and metastasis. Blood 97, 192–197 (2001).
  CAS PubMed Google Scholar
• Street, S. E., Trapani, J. A., MacGregor, D. & Smyth, M. J. Suppression of lymphoma and epithelial malignancies effected by interferon-γ. J. Exp. Med. 196, 129–134 (2002). Reveals that the functions of IFNγ and perforin in surveillance of spontaneous malignancies are not completely overlapping.
  CAS PubMed PubMed Central Google Scholar
• Enzler, T. et al. Deficiencies of GM-CSF and interferon-γ link inflammation and cancer. J. Exp. Med. 197, 1213–1219 (2003).
  CAS PubMed PubMed Central Google Scholar
• Gao, Y. et al. γδ T cells provide an early source of interferon-γ in tumor immunity. J. Exp. Med. 198, 433–442 (2003). Shows the importance of IFNγ production by γδ T cells in cancer immunosurveillance.
  CAS PubMed PubMed Central Google Scholar
• Tripp, C. S., Wolf, S. F. & Unanue, E. R. Interleukin 12 and tumor necrosis factor α are costimulators of interferon-γ production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiologic antagonist. Proc. Natl Acad. Sci. USA 90, 3725–3729 (1993).
  CAS PubMed PubMed Central Google Scholar
• Yang, J., Murphy, T. L., Ouyang, W. & Murphy, K. M. Induction of interferon-γ production in TH1 CD4+ T cells: evidence for two distinct pathways for promoter activation. Eur. J. Immunol. 29, 548–555 (1999).
  CAS PubMed Google Scholar
• Nastala, C. L. et al. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J. Immunol. 153, 1697–1706 (1994).
  CAS PubMed Google Scholar
• Noguchi, Y., Jungbluth, A., Richards, E. & Old, L. J. Effect of interleukin 12 on tumor induction by 3-methylcholanthrene. Proc. Natl Acad. Sci. USA 93, 11798–11801 (1996).
  CAS PubMed PubMed Central Google Scholar
• Smyth, M. J., Crowe, N. Y. & Godfrey, D. I. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int. Immunol. 13, 459–463 (2001).
  CAS PubMed Google Scholar
• Gresser, I., Bourali, C., Levy, J. P., Fontaine-Brouty-Boye, D. & Thomas, M. T. Increased survival in mice inoculated with tumor cells and treated with interferon preparations. Proc. Natl Acad. Sci. USA 63, 51–57 (1969).
  CAS PubMed PubMed Central Google Scholar
• Gresser, I., Maury, C. & Brouty-Boye, D. Mechanism of the antitumour effect of interferon in mice. Nature 239, 167–168 (1972).
  CAS PubMed Google Scholar
• Belardelli, F., Ferrantini, M., Proietti, E. & Kirkwood, J. M. Interferon-α in tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 13, 119–134 (2002).
  CAS PubMed Google Scholar
• Reid, L. M. et al. Influence of anti-mouse interferon serum on the growth and metastasis of tumor cells persistently infected with virus and of human prostatic tumors in athymic nude mice. Proc. Natl Acad. Sci. USA 78, 1171–1175 (1981).
  CAS PubMed PubMed Central Google Scholar
• Gresser, I., Belardelli, F., Maury, C., Maunoury, M. T. & Tovey, M. G. Injection of mice with antibody to interferon enhances the growth of transplantable murine tumors. J. Exp. Med. 158, 2095–2107 (1983).
  CAS PubMed Google Scholar
• Picaud, S., Bardot, B., De Maeyer, E. & Seif, I. Enhanced tumor development in mice lacking a functional type I interferon receptor. J. Interferon Cytokine Res. 22, 457–462 (2002).
  CAS PubMed Google Scholar
• Sheehan, K. C. F. et al. Blocking monoclonal antibodies specific for mouse IFN-α/β receptor subunit 1 (IFNAR1) from mice immunized by in vivo hydrodynamic transfection. J. Interferon Cytokine Res. 26, 809–819 (2006).
  Google Scholar
• Hahn, W. C. & Weinberg, R. A. Rules for making human tumor cells. N. Engl. J. Med. 347, 1593–1603 (2002).
  CAS PubMed Google Scholar
• Vogelstein, B. & Kinzler, K. W. Cancer genes and the pathways they control. Nature Med. 10, 789–799 (2004).
  CAS PubMed Google Scholar
• Wheelock, E. F., Weinhold, K. J. & Levich, J. The tumor dormant state. Adv. Cancer Res. 34, 107–140 (1981).
  CAS PubMed Google Scholar
• Uhr, J. W., Tucker, T., May, R. D., Siu, H. & Vitetta, E. S. Cancer dormancy: studies of the murine BCL1 lymphoma. Cancer Res. 51, 5045s–5053s (1991).
  CAS PubMed Google Scholar
• Smyth, M. J. et al. NKG2D function protects the host from tumor initiation. J. Exp. Med. 202, 583–588 (2005). Provides evidence that supports the idea of perforin-dependent cancer immunoediting of NKG2D ligands.
  CAS PubMed PubMed Central Google Scholar
• Smyth, M. J. et al. Differential tumor surveillance by natural killer (NK) and NKT cells. J. Exp. Med. 191, 661–668 (2000).
  CAS PubMed PubMed Central Google Scholar
• Willimsky, G. & Blankenstein, T. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 437, 141–146 (2005).
  CAS PubMed Google Scholar
• Dunn, G. P., Sheehan, K. C., Old, L. J. & Schreiber, R. D. IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression. Cancer Res. 65, 3447–3453 (2005).
  CAS PubMed Google Scholar
• Sanda, M. G. et al. Molecular characterization of defective antigen processing in human prostate cancer. J. Natl Cancer Inst. 87, 280–285 (1995).
  CAS PubMed Google Scholar
• Wong, L. H. et al. Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3γ. J. Biol. Chem. 272, 28779–28785 (1997).
  CAS PubMed Google Scholar
• Xi, S. et al. Decreased STAT1 expression by promoter methylation in squamous cell carcinogenesis. J. Natl Cancer Inst. 98, 181–189 (2006).
  CAS PubMed Google Scholar
• Wellbrock, C. et al. STAT5 contributes to interferon resistance of melanoma cells. Curr. Biol. 15, 1629–1639 (2005).
  CAS PubMed Google Scholar
• Seliger, B., Maeurer, M. J. & Ferrone, S. Antigen-processing machinery breakdown and tumor growth. Immunol. Today 21, 455–464 (2000).
  CAS PubMed Google Scholar
• Algarra, I., Cabrera, T. & Garrido, F. The HLA crossroad in tumor immunology. Hum. Immunol. 61, 65–73 (2000).
  CAS PubMed Google Scholar
• Marincola, F. M., Jaffee, E. M., Hicklin, D. J. & Ferrone, S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv. Immunol. 74, 181–273 (2000).
  CAS PubMed Google Scholar
• Li, Z. et al. Expression of SOCS-1, suppressor of cytokine signalling-1, in human melanoma. J. Invest. Dermatol. 123, 737–745 (2004).
  CAS PubMed Google Scholar
• Dighe, A. S., Farrar, M. A. & Schreiber, R. D. Inhibition of cellular responsiveness to interferon-γ (IFNγ) induced by overexpression of inactive forms of the IFNγ receptor. J. Biol. Chem. 268, 10645–10653 (1993).
  CAS PubMed Google Scholar
• Coughlin, C. M. et al. Tumor cell responses to IFNγ affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity 9, 25–34 (1998).
  CAS PubMed Google Scholar
• Beatty, G. & Paterson, Y. IFN-γ-dependent inhibition of tumor angiogenesis by tumor-infiltrating CD4+ T cells requires tumor responsiveness to IFN-γ. J. Immunol. 166, 2276–2282 (2001).
  CAS PubMed Google Scholar
• Bui, J. D., Carayannopoulos, L. N., Lanier, L. L., Yokoyama, W. M. & Schreiber, R. D. IFN-dependent down-regulation of the NKG2D ligand H60 on tumors. J. Immunol. 176, 905–913 (2006).
  CAS PubMed Google Scholar
• Chin, Y. E. et al. Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21WAF1/CIP1 mediated by STAT1. Science 272, 719–722 (1996).
  CAS PubMed Google Scholar
• Bromberg, J. F., Horvath, C. M., Wen, Z., Schreiber, R. D. & Darnell, J. E. Jr. Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon α and interferon γ. Proc. Natl Acad. Sci. USA 93, 7673–7678 (1996).
  CAS PubMed PubMed Central Google Scholar
• Chin, Y. E., Kitagawa, M., Kuida, K., Flavell, R. A. & Fu, X. Y. Activation of the STAT signaling pathway can cause expression of caspase 1 and apoptosis. Mol. Cell. Biol. 17, 5328–5337 (1997).
  CAS PubMed PubMed Central Google Scholar
• Xu, X., Fu, X. Y., Plate, J. & Chong, A. S. IFN-γ induces cell growth inhibition by Fas-mediated apoptosis: requirement of STAT1 protein for up-regulation of Fas and FasL expression. Cancer Res. 58, 2832–2837 (1998).
  CAS PubMed Google Scholar
• Meng, R. D. & El-Deiry, W. S. p53-independent upregulation of KILLER/DR5 TRAIL receptor expression by glucocorticoids and interferon-γ. Exp. Cell Res. 262, 154–169 (2001).
  CAS PubMed Google Scholar
• Luster, A. D. & Leder, P. IP-10, a C-X-C-chemokine, elicits a potent thymus-dependent antitumor response in vivo. J. Exp. Med. 178, 1057–1065 (1993).
  CAS PubMed Google Scholar
• Mumberg, D. et al. CD4+ T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ. Proc. Natl Acad. Sci. USA 96, 8633–8638 (1999).
  CAS PubMed PubMed Central Google Scholar
• Fallarino, F. & Gajewski, T. F. Differentiation of antitumor CTL in vivo requires host expression of Stat1. J. Immunol. 163, 4109–4113 (1999).
  CAS PubMed Google Scholar
• Kacha, A. K., Fallarino, F., Markiewicz, M. A. & Gajewski, T. F. Spontaneous rejection of poorly immunogenic P1.HTR tumors by Stat6-deficient mice. J. Immunol. 165, 6024–6028 (2000).
  CAS PubMed Google Scholar
• Nishikawa, H. et al. IFN-γ controls the generation/activation of CD4+CD25+ regulatory T cells in antitumor immune response. J. Immunol. 175, 4433–4440 (2005). Illustrates the important influence of IFNγ on T Reg -cell-dependent suppression of cancer immunosurveillance.
  CAS PubMed Google Scholar
• Nishikawa, H. et al. CD4+ CD25+ T cells responding to serologically defined autoantigens suppress antitumor immune responses. Proc. Natl Acad. Sci. USA 100, 10902–10906 (2003).
  CAS PubMed PubMed Central Google Scholar
• de Visser, K. E., Eichten, A. & Coussens, L. M. Paradoxical roles of the immune system during cancer development. Nature Rev. Cancer 6, 24–37 (2006).
  CAS Google Scholar
• Kawanishi, S., Hiraku, Y., Pinlaor, S. & Ma, N. Oxidative and nitrative DNA damage in animals and patients with inflammatory diseases in relation to inflammation-related carcinogenesis. Biol. Chem. 387, 365–372 (2006).
  CAS PubMed Google Scholar
• Langowski, J. L. et al. IL-23 promotes tumour incidence and growth. Nature 442, 461–465 (2006). Details the importance of the IL-12 and IL-23 cytokine milieu in determining the balance between the tumour-promoting and tumour-suppressive actions of the antitumour immune response. And begins to synthesize, into one process, the seemingly contradictory processes of tumour-promoting inflammatory reactions and host-protective immune responses.
  CAS PubMed Google Scholar
• Moore, R. J. et al. Mice deficient in tumor necrosis factor-α are resistant to skin carcinogenesis. Nature Med. 5, 828–831 (1999).
  CAS PubMed Google Scholar
• Hanada, T. et al. IFNγ-dependent, spontaneous development of colorectal carcinomas in SOCS1-deficient mice. J. Exp. Med. 203, 1391–1397 (2006).
  CAS PubMed PubMed Central Google Scholar
• Brassard, D. L., Grace, M. J. & Bordens, R. W. Interferon-α as an immunotherapeutic protein. J. Leukoc. Biol. 71, 565–581 (2002).
  CAS PubMed Google Scholar
• Belardelli, F., Gresser, I., Maury, C. & Maunoury, M. T. Antitumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend leukemia cells. I. Int. J. Cancer 30, 813–820 (1982).
  CAS PubMed Google Scholar
• Lesinski, G. B. et al. The antitumor effects of IFN-α are abrogated in a STAT1-deficient mouse. J. Clin. Invest. 112, 170–180 (2003).
  CAS PubMed PubMed Central Google Scholar
• Bogdan, C., Mattner, J. & Schleicher, U. The role of type I interferons in non-viral infections. Immunol. Rev. 202, 33–48 (2004).
  CAS PubMed Google Scholar
• Kerbel, R. & Folkman, J. Clinical translation of angiogenesis inhibitors. Nature Rev. Cancer 2, 727–739 (2002).
  CAS Google Scholar
• Takaoka, A. et al. Integration of interferon-α/β signalling to p53 responses in tumour suppression and antiviral defence. Nature 424, 516–523 (2003).
  CAS PubMed Google Scholar
• Silverman, R. H. Implications for RNase L in prostate cancer biology. Biochemistry 42, 1805–1812 (2003).
  CAS PubMed Google Scholar
• Carpten, J. et al. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nature Genet. 30, 181–184 (2002).
  CAS PubMed Google Scholar
• Casey, G. et al. RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nature Genet. 32, 581–583 (2002).
  CAS PubMed Google Scholar
• Urisman, A. et al. Identification of a novel γ retrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. PLoS Pathog. 2, e25 (2006).
  PubMed PubMed Central Google Scholar
• Kirkwood, J. M. et al. Interferon α-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J. Clin. Oncol. 14, 7–17 (1996).
  CAS PubMed Google Scholar
• Gogas, H. et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N. Engl. J. Med. 354, 709–718 (2006).
  CAS PubMed Google Scholar
• Gleave, M. E. et al. Interferon γ-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group. N. Engl. J. Med. 338, 1265–1271 (1998).
  CAS PubMed Google Scholar
• Wiesenfeld, M. et al. Controlled clinical trial of interferon-γ as postoperative surgical adjuvant therapy for colon cancer. J. Clin. Oncol. 13, 2324–2329 (1995).
  CAS PubMed Google Scholar
• Jett, J. R. et al. Phase III trial of recombinant interferon γ in complete responders with small-cell lung cancer. J. Clin. Oncol. 12, 2321–2326 (1994).
  CAS PubMed Google Scholar
• Windbichler, G. H. et al. Interferon-γ in the first-line therapy of ovarian cancer: a randomized phase III trial. Br. J. Cancer 82, 1138–1144 (2000).
  CAS PubMed PubMed Central Google Scholar
• Giannopoulos, A. et al. The immunomodulating effect of interferon-γ intravesical instillations in preventing bladder cancer recurrence. Clin. Cancer Res. 9, 5550–5558 (2003).
  CAS PubMed Google Scholar
• Lienard, D., Eggermont, A. M., Kroon, B. B., Schraffordt Koops, H. & Lejeune, F. J. Isolated limb perfusion in primary and recurrent melanoma: indications and results. Semin. Surg. Oncol. 14, 202–209 (1998).
  CAS PubMed Google Scholar
• Gasser, S. & Raulet, D. H. The DNA damage response arouses the immune system. Cancer Res. 66, 3959–3962 (2006).
  CAS PubMed Google Scholar
• Zhang, J. J. et al. Two contact regions between Stat1 and CBP/p300 in interferon γ signaling. Proc. Natl Acad. Sci. USA 93, 15092–15096 (1996).
  CAS PubMed PubMed Central Google Scholar
• DaFonseca, C. J., Shu, F. & Zhang, J. J. Identification of two residues in MCM5 critical for the assembly of MCM complexes and Stat1-mediated transcription activation in response to IFN-γ. Proc. Natl Acad. Sci. USA 98, 3034–3039 (2001).
  CAS PubMed PubMed Central Google Scholar
• Schreiber, G. H. & Schreiber, R. D. in The Cytokine Handbook 4th edn (eds Thomson, A. & Lotze, M.) 567–601 (Academic, London, 2003).
  Google Scholar
• Alexander, W. S. et al. SOCS1 is a critical inhibitor of interferon γ signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell 98, 597–608 (1999).
  CAS PubMed Google Scholar
• Marine, J. C. et al. SOCS1 deficiency causes a lymphocyte-dependent perinatal lethality. Cell 98, 609–616 (1999).
  CAS PubMed Google Scholar
• Liu, B. et al. PIAS1 selectively inhibits interferon-inducible genes and is important in innate immunity. Nature Immunol. 5, 891–898 (2004).
  CAS Google Scholar
• Platanias, L. C. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nature Rev. Immunol. 5, 375–386 (2005).
  CAS Google Scholar
• Pestka, S., Krause, C. D. & Walter, M. R. Interferons, interferon-like cytokines, and their receptors. Immunol. Rev. 202, 8–32 (2004).
  CAS PubMed Google Scholar
• Karaghiosoff, M. et al. Partial impairment of cytokine responses in Tyk2-deficient mice. Immunity 13, 549–560 (2000).
  CAS PubMed Google Scholar
• Shimoda, K. et al. Tyk2 plays a restricted role in IFNα signaling, although it is required for IL-12-mediated T cell function. Immunity 13, 561–571 (2000).
  CAS PubMed Google Scholar
• Girardi, M. et al. Regulation of cutaneous malignancy by γδ T cells. Science 294, 605–609 (2001).
  CAS PubMed Google Scholar
• Girardi, M. et al. The distinct contributions of murine T cell receptor (TCR)γδ+ and TCRαβ+ T cells to different stages of chemically induced skin cancer. J. Exp. Med. 198, 747–755 (2003).
  CAS PubMed PubMed Central Google Scholar
• Smyth, M. J. et al. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J. Exp. Med. 192, 755–760 (2000).
  CAS PubMed PubMed Central Google Scholar
• Hayashi, T. & Faustman, D. L. Development of spontaneous uterine tumors in low molecular mass polypeptide-2 knockout mice. Cancer Res. 62, 24–27 (2002).
  CAS PubMed Google Scholar
• Nishikawa, H. et al. Accelerated chemically induced tumor development mediated by CD4+CD25+ regulatory T cells in wild-type hosts. Proc. Natl Acad. Sci. USA 102, 9253–9257 (2005).
  CAS PubMed PubMed Central Google Scholar
• Mitra-Kaushik, S., Harding, J., Hess, J., Schreiber, R. & Ratner, L. Enhanced tumorigenesis in HTLV-1 _tax_-transgenic mice deficient in interferon-γ. Blood 104, 3305–3311 (2004).
  CAS PubMed Google Scholar
• Street, S. E. et al. Innate immune surveillance of spontaneous B cell lymphomas by natural killer cells and γδ T cells. J. Exp. Med. 199, 879–884 (2004).
  CAS PubMed PubMed Central Google Scholar
• van den Broek, M. F. et al. Decreased tumor surveillance in perforin-deficient mice. J. Exp. Med. 184, 1781–1790 (1996).
  CAS PubMed Google Scholar
• Cretney, E. et al. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J. Immunol. 168, 1356–1361 (2002).
  CAS PubMed Google Scholar
• Zerafa, N. et al. TRAIL deficiency accelerates hematological malignancies. J. Immunol. 175, 5586–5590 (2005).
  CAS PubMed Google Scholar
• Hayakawa, Y., Rovero, S., Forni, G. & Smyth, M. J. α-Galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis. Proc. Natl Acad. Sci. USA 100, 9464–9469 (2003).
  CAS PubMed PubMed Central Google Scholar
• Barchet, W., Blasius, A., Cella, M. & Colonna, M. Plasmacytoid dendritic cells: in search of their niche in immune responses. Immunol. Res. 32, 75–84 (2005).
  CAS PubMed Google Scholar
• Ikeda, H., Old, L. J. & Schreiber, R. D. The roles of IFNγ in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev. 13, 95–109 (2002).
  CAS PubMed Google Scholar
• Galon, J. et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960–1964 (2006).
  CAS PubMed Google Scholar